Peter AbbinkRafael A. LaroccaWanwisa DejnirattisaiRebecca PetersonJoseph P. NkololaErica N. BorducchiPiyada SupasaJuthathip MongkolsapayaGavin R. ScreatonDan H. BarouchUniversity of OxfordMassachusetts Institute of TechnologyImperial College LondonFaculty of Medicine, Siriraj Hospital, Mahidol UniversityHarvard Medical School2019-08-232019-08-232018-06-01Nature Medicine. Vol.24, No.6 (2018), 721-7231546170X107889562-s2.0-85048016859https://repository.li.mahidol.ac.th/handle/20.500.14594/45157© 2018 The Author(s). Strategies to treat Zika virus (ZIKV) infection in dengue virus (DENV)-endemic areas are urgently needed. Here we show that a DENV-specific antibody against the E-dimer epitope (EDE) potently cross-neutralizes ZIKV and provides robust therapeutic efficacy as well as prophylactic efficacy against ZIKV in rhesus monkeys. Viral escape was not detected, suggesting a relatively high bar to escape. These data demonstrate the potential for antibody-based therapy and prevention of ZIKV.Mahidol UniversityBiochemistry, Genetics and Molecular BiologyArticleSCOPUS10.1038/s41591-018-0056-0